Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
<h4>Background and aims</h4>Chronic hepatitis C (HCV) is a liver disease affecting over 3 million Americans. Liver biopsy is the gold standard for assessing liver fibrosis and is used as a benchmark for initiating treatment, though it is expensive and carries risks of complications. Fibr...
Main Authors: | Shan Liu, Michaël Schwarzinger, Fabrice Carrat, Jeremy D Goldhaber-Fiebert |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22164204/?tool=EBI |
Similar Items
-
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States.
by: Shan Liu, et al.
Published: (2013-01-01) -
Estimating the cost of cervical cancer screening in five developing countries
by: Goldie Sue J, et al.
Published: (2006-08-01) -
Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence
by: Lauren E. Cipriano, et al.
Published: (2018-05-01) -
Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study.
by: Eugene Lin, et al.
Published: (2018-03-01) -
Modeling the Cost-Effectiveness of Interventions to Prevent Plague in Madagascar
by: Giovanni S. P. Malloy, et al.
Published: (2021-06-01)